Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia

INTRODUCTION: Imatinib mesylate (IM), a selective inhibitor of the BCR-ABL tyrosine kinase, is a well-established first-line treatment for chronic myeloid leukemia (CML). IM is metabolized mainly by cytochrome P450 (CYP) in the liver, specifically the CYP3A4 and CYP3A5 enzymes. Polymorphisms in thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Maddin, Najlaa, Husin, Azlan, Gan, Siew Hua, Aziz, Baba Abdul, Ankathil, Ravindran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315081/
https://www.ncbi.nlm.nih.gov/pubmed/28261657
http://dx.doi.org/10.1007/s40487-016-0035-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315081/
https://www.ncbi.nlm.nih.gov/pubmed/28261657
http://dx.doi.org/10.1007/s40487-016-0035-x

Ejemplares similares